Lothar Roessig

6.2k total citations · 3 hit papers
63 papers, 3.7k citations indexed

About

Lothar Roessig is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Lothar Roessig has authored 63 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Cardiology and Cardiovascular Medicine, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Economics and Econometrics. Recurrent topics in Lothar Roessig's work include Heart Failure Treatment and Management (45 papers), Cardiovascular Function and Risk Factors (34 papers) and Cardiac pacing and defibrillation studies (17 papers). Lothar Roessig is often cited by papers focused on Heart Failure Treatment and Management (45 papers), Cardiovascular Function and Risk Factors (34 papers) and Cardiac pacing and defibrillation studies (17 papers). Lothar Roessig collaborates with scholars based in Germany, United States and Singapore. Lothar Roessig's co-authors include Carolyn S.P. Lam, Burkert Pieske, Piotr Ponikowski, Javed Butler, Justin A. Ezekowitz, Adriaan A. Voors, Adrian F. Hernandez, Kevin J. Anstrom, Scott D. Solomon and Mahesh J. Patel and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Lothar Roessig

60 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

2020 781 citations Burkert Pieske, Kevin J. Anstrom et al. profile →
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction

2015 281 citations Mihai Gheorghiade, Stephen J. Greene et al. JAMA profile →
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction

2020 184 citations Paul W. Armstrong, Carolyn S.P. Lam et al. JAMA profile →

Peers

Countries citing papers authored by Lothar Roessig

Since Specialization

Citations

This map shows the geographic impact of Lothar Roessig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lothar Roessig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lothar Roessig more than expected).

Fields of papers citing papers by Lothar Roessig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lothar Roessig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lothar Roessig. The network helps show where Lothar Roessig may publish in the future.

Co-authorship network of co-authors of Lothar Roessig

This figure shows the co-authorship network connecting the top 25 collaborators of Lothar Roessig. A scholar is included among the top collaborators of Lothar Roessig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lothar Roessig. Lothar Roessig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GenePHIT Phase 2 Study Design: A Double Blind, Placebo-controlled Trial To Assess Efficacy, Safety, And Tolerability Of Ab-1002 Gene Therapy In Adults With Heart Failure 2025 ·Journal of Cardiac Failure ·Timothy D. Henry, Eugene Chung, (unknown), (unknown), Lothar Roessig, (unknown), Sandeep K. Reddy, (unknown), (unknown), Canwen Jiang, Jude Samulski, Evangelia G. Kranias, Anna Tretiakova, Roger J. Hajjar	2
2	GenePHIT phase 2 study design: a double blind, placebo-controlled trial to assess efficacy, safety, and tolerability of AB-1002 gene therapy in adults with heart failure 2024 ·European Heart Journal ·Timothy D. Henry, Eugene Chung, M.F. Alvisi, Farah Sethna, Lothar Roessig, Lisa Roberts, Sandeep K. Reddy, (unknown), Sameh Mikhail, Chen Jiang, Jude Samulski, Evangelia G. Kranias, Anna Tretiakova, Roger J. Hajjar	1
3	Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF 2024 ·Circulation Heart Failure ·Christopher R. deFilippi, Palak Shah, Sanjiv J. Shah, Wendimagegn Alemayehu, Carolyn S.P. Lam, Javed Butler, Lothar Roessig, Christopher M. O’Connor, Cynthia M. Westerhout, Paul W. Armstrong, (unknown)	2
4	Relationship Between Baseline Electrocardiographic Measurements and Outcomes in Patients with High-Risk Heart Failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) Trial 2023 ·European Journal of Heart Failure ·Haran Yogasundaram, Yinggan Zheng, (unknown), Justin A. Ezekowitz, Piotr Ponikowski, Carolyn S.P. Lam, Christopher M. O’Connor, Robert O. Blaustein, Lothar Roessig, (unknown), Cynthia M. Westerhout, Paul W. Armstrong, Roopinder K. Sandhu, (unknown)	3
5	Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction 2023 ·JACC Heart Failure ·Padma Kaul, (unknown), Carolyn S.P. Lam, Cynthia M. Westerhout, John A. Spertus, Kevin J. Anstrom, Robert O. Blaustein, Justin A. Ezekowitz, Burkert Pieske, Lothar Roessig, Javed Butler, Paul W. Armstrong	11
6	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry 2022 ·Journal of Cardiac Failure ·Stephen J. Greene, Justin A. Ezekowitz, Kevin J. Anstrom, (unknown), Michael M. Givertz, Ileana L. Piña, Christopher M. O’Connor, Joerg Koglin, Lothar Roessig, Adrian F. Hernandez, Paul W. Armstrong, Robert J. Mentz	33
7	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial 2022 ·European Journal of Heart Failure ·Michele Senni, Wendimagegn Alemayehu, David Sim, Frank Edelmann, Javed Butler, Justin A. Ezekowitz, Adrian F. Hernandez, Carolyn S.P. Lam, Christopher M. O’Connor, Burkert Pieske, Piotr Ponikowski, Lothar Roessig, Adriaan A. Voors, Cynthia M. Westerhout, Ciaran J. McMullan, Paul W. Armstrong, (unknown)	20
8	BASELINE CARDIAC TROPONIN T, CLINICAL OUTCOMES AND VERICIGUAT TREATMENT EFFECT IN HEART FAILURE WITH REDUCED EJECTION FRACTION STUDY: INSIGHTS FROM THE VICTORIA TRIAL 2021 ·Journal of the American College of Cardiology ·Christopher R. deFilippi, Wendimagegn Alemayehu, Adriaan A. Voors, David M. Kaye, (unknown), Javed Butler, Justin A. Ezekowitz, Adrían V. Hernández, Joerg Koglin, Carolyn S.P. Lam, Burkert Pieske, Piotr Ponikowski, Lothar Roessig, Stephen L. Seliger, Cynthia M. Westerhout, Paul W. Armstrong, Christopher O’Connor	1
9	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA ( Vericiguat Global Study in Subjects with HFrEF ) trial 2021 ·European Journal of Heart Failure ·Adriaan A. Voors, Hillary Mulder, Eugene B. Reyes, Martín Cowie, Johan Lassus, Adrian F. Hernandez, Justin A. Ezekowitz, Javed Butler, Christopher M. O’Connor, Joerg Koglin, Carolyn S.P. Lam, Burkert Pieske, Lothar Roessig, Piotr Ponikowski, Kevin J. Anstrom, Paul W. Armstrong, (unknown)	66
10	Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials 2021 ·Health and Quality of Life Outcomes ·Theresa Coles, Adrian F. Hernandez, Bryce B. Reeve, Karon F. Cook, Michael C. Edwards, Marc Boutin, Elizabeth Nicole Bush, Arnold Degboe, Lothar Roessig, Amy E. Rudolph, Pauline McNulty, Nikunj Patel, (unknown), Margaret Vernon, Michael Woloschak, Gustavo Büchele, John A. Spertus, Matthew T. Roe, (unknown), Kevin P. Weinfurt	10
11	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction breakdown → 2020 ·JAMA ·Paul W. Armstrong, Carolyn S.P. Lam, Kevin J. Anstrom, Justin A. Ezekowitz, Adrian F. Hernandez, Christopher M. O’Connor, Burkert Pieske, Piotr Ponikowski, Sanjiv J. Shah, Scott D. Solomon, Adriaan A. Voors, Lilin She, Vanja Vlajnic, (unknown), Luke Bamber, Robert O. Blaustein, Lothar Roessig, Javed Butler, (unknown)	184
12	Evaluation of High-Sensitivity C-Reactive Protein and Uric Acid in Vericiguat-Treated Patients with Heart Failure with Reduced Ejection Fraction 2020 ·European Journal of Heart Failure ·Frank Kramer, Sebastian Voß, Lothar Roessig, (unknown), Javed Butler, Carolyn S.P. Lam, Aldo P. Maggioni, Sanjiv J. Shah, Burkert Pieske	30
13	Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) Trial 2019 ·European Journal of Heart Failure ·Burkert Pieske, Mahesh J. Patel, Cynthia M. Westerhout, Kevin J. Anstrom, Javed Butler, Justin A. Ezekowitz, Adrian F. Hernandez, Joerg Koglin, Carolyn S.P. Lam, Piotr Ponikowski, Lothar Roessig, Adriaan A. Voors, Christopher M. O’Connor, Paul W. Armstrong	62
14	Heart Failure Clinical Trials in East and Southeast Asia 2016 ·JACC Heart Failure ·Robert J. Mentz, Lothar Roessig, Barry Greenberg, Naoki Sato, Kaori Shinagawa, Daniel Yeo, Bernard W.K. Kwok, Eugenio B Reyes, Henry Krum, Burkert Pieske, Stephen J. Greene, Andrew P. Ambrosy, Jacob P. Kelly, Faı̈ez Zannad, Bertram Pitt, Carolyn S.P. Lam	41
15	Agents with Vasodilator Properties in Acute Heart Failure: How to Design Successful Trials 2015 ·European Journal of Heart Failure ·Alexandre Mebazaa, Dan Longrois, Marco Metra, Christian Mueller, Mark Richards, Lothar Roessig, Marie France Séronde, Naoki Sato, Norman Stockbridge, Wendy Gattis Stough, Ángeles Alonso, Robert Cody, Nancy Cook Bruns, Mihai Gheorghiade, Johannes Holzmeister, Sai͏̈d Laribi, Faı̈ez Zannad	18
16	Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1) 2014 ·CHEST Journal ·Diana Bonderman, Ingrid Pretsch, Regina Steringer‐Mascherbauer, Pavel Jansa, Stephan Rosenkranz, Caroline Tufaro, Andja Bojic, Carolyn S.P. Lam, Reiner Frey, Michael Ochan Kilama, Sigrun Unger, Lothar Roessig, Iréne Lang	198
17	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries 2014 ·American Heart Journal ·Stephen J. Greene, Ami N. Shah, Javed Butler, Andrew P. Ambrosy, Stefan D. Anker, Ovidiu Chioncel, Sean P. Collins, Wilfried Dinh, Preston Dunnmon, Gregg C. Fonarow, Carolyn S.P. Lam, Robert J. Mentz, Burkert Pieske, Lothar Roessig, Giuseppe Rosano, Naoki Sato, Muthiah Vaduganathan, Mihai Gheorghiade	23
18	Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction 2013 ·Circulation ·Diana Bonderman, Stefano Ghio, Stephan B. Felix, Hossein Ardeschir Ghofrani, Evangelos D. Michelakis, Veselin Mitrović, Ronald J. Oudiz, Francis Boateng, (unknown), Lothar Roessig, Marc J. Semigran	241
19	Left Ventricular Systolic Dysfunction Associated with Pulmonary Hypertension Riociguat Trial (LEPHT): Rationale and Design 2012 ·European Journal of Heart Failure ·Stefano Ghio, Diana Bonderman, Stephan B. Felix, Hossein Ardeschir Ghofrani, Evangelos D. Michelakis, Veselin Mitrović, Ronald J. Oudiz, Reiner Frey, Lothar Roessig, Marc J. Semigran	21
20	Soluble guanylate cyclase: a potential therapeutic target for heart failure 2012 ·Heart Failure Reviews ·Mihai Gheorghiade, Catherine N. Marti, Hani N. Sabbah, Lothar Roessig, Stephen J. Greene, Michael Böhm, John C. Burnett, Umberto Campia, John G.F. Cleland, Sean P. Collins, Gregg C. Fonarow, Phillip D. Levy, Marco Metra, Bertram Pitt, Piotr Ponikowski, Naoki Sato, Adriaan A. Voors, Johannes-Peter Stasch, Javed Butler	117

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact